308 related articles for article (PubMed ID: 31597698)
41. Prognostic impact of molecular genetic alterations in hepatoblastoma.
von Schweinitz D; Kraus JA; Albrecht S; Koch A; Fuchs J; Pietsch T
Med Pediatr Oncol; 2002 Feb; 38(2):104-8. PubMed ID: 11813174
[TBL] [Abstract][Full Text] [Related]
42. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
43. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Loesch R; Caruso S; Paradis V; Godard C; Gougelet A; Renault G; Picard S; Tanaka I; Renoux-Martin Y; Perret C; Taketo MM; Zucman-Rossi J; Colnot S
J Hepatol; 2022 Aug; 77(2):424-435. PubMed ID: 35257829
[TBL] [Abstract][Full Text] [Related]
44. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
Buendia MA
Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
[TBL] [Abstract][Full Text] [Related]
45. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
Gene; 2024 May; 908():148292. PubMed ID: 38369247
[TBL] [Abstract][Full Text] [Related]
46. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
47. Intracellular localization of beta-catenin expression plays a possible prognostic role on the outcome of hepatoblastoma patients.
Celtik U; Dokumcu Z; Divarci E; Guler E; Ataseven E; Nart D; Yilmaz F; Celik A; Ergün O
Pediatr Surg Int; 2020 Jul; 36(7):817-825. PubMed ID: 32436062
[TBL] [Abstract][Full Text] [Related]
48. CITED1 expression in liver development and hepatoblastoma.
Murphy AJ; de Caestecker C; Pierce J; Boyle SC; Ayers GD; Zhao Z; Libes JM; Correa H; Walter T; Huppert SS; Perantoni AO; de Caestecker MP; Lovvorn HN
Neoplasia; 2012 Dec; 14(12):1153-63. PubMed ID: 23308048
[TBL] [Abstract][Full Text] [Related]
49. Down-regulation of dishevelled-2 inhibits cell proliferation and invasion in hepatoblastoma.
Huang S; Chen J; Tian R; Wang J; Xie C; Gao H; Shan Y; Hong J; Zhang Z; Xu M; Gu S
Pediatr Blood Cancer; 2018 Jul; 65(7):e27032. PubMed ID: 29528187
[TBL] [Abstract][Full Text] [Related]
50. Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice.
Wang H; Dolezal JM; Kulkarni S; Lu J; Mandel J; Jackson LE; Alencastro F; Duncan AW; Prochownik EV
J Biol Chem; 2018 Sep; 293(38):14740-14757. PubMed ID: 30087120
[TBL] [Abstract][Full Text] [Related]
51. β-Catenin mutations in 2 nested stromal epithelial tumors of the liver--a neoplasia with defective mesenchymal-epithelial transition.
Assmann G; Kappler R; Zeindl-Eberhart E; Schmid I; Häberle B; Graeb C; Jung A; Müller-Höcker J
Hum Pathol; 2012 Nov; 43(11):1815-27. PubMed ID: 22749188
[TBL] [Abstract][Full Text] [Related]
52. Phase separation of YAP mediated by coiled-coil domain promotes hepatoblastoma proliferation via activation of transcription.
Mao S; Liu Q; Wu H; Zhu J; Xie Y; Ma J; Zhen N; Pan Q
J Gastroenterol Hepatol; 2023 Aug; 38(8):1398-1407. PubMed ID: 36908026
[TBL] [Abstract][Full Text] [Related]
53. DLK1/DIO3 locus upregulation by a β-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis.
Sanceau J; Poupel L; Joubel C; Lagoutte I; Caruso S; Pinto S; Desbois-Mouthon C; Godard C; Hamimi A; Montmory E; Dulary C; Chantalat S; Roehrig A; Muret K; Saint-Pierre B; Deleuze JF; Mouillet-Richard S; Forné T; Grosset CF; Zucman-Rossi J; Colnot S; Gougelet A
Mol Ther; 2024 Apr; 32(4):1125-1143. PubMed ID: 38311851
[TBL] [Abstract][Full Text] [Related]
54. Circ-CCT2 Activates Wnt/β-catenin Signaling to Facilitate Hepatoblastoma Development by Stabilizing PTBP1 mRNA.
Zhu Q; Hu Y; Jiang W; Ou ZL; Yao YB; Zai HY
Cell Mol Gastroenterol Hepatol; 2024; 17(2):175-197. PubMed ID: 37866478
[TBL] [Abstract][Full Text] [Related]
55. Multifocal hepatic neoplasia in 3 children with APC gene mutation.
Gupta A; Sheridan RM; Towbin A; Geller JI; Tiao G; Bove KE
Am J Surg Pathol; 2013 Jul; 37(7):1058-66. PubMed ID: 23715166
[TBL] [Abstract][Full Text] [Related]
56. In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors.
Sangkhathat S; Kusafuka T; Miao J; Yoneda A; Nara K; Yamamoto S; Kaneda Y; Fukuzawa M
Int J Oncol; 2006 Mar; 28(3):715-22. PubMed ID: 16465377
[TBL] [Abstract][Full Text] [Related]
57. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.
Park WS; Oh RR; Park JY; Kim PJ; Shin MS; Lee JH; Kim HS; Lee SH; Kim SY; Park YG; An WG; Kim HS; Jang JJ; Yoo NJ; Lee JY
J Pathol; 2001 Apr; 193(4):483-90. PubMed ID: 11276007
[TBL] [Abstract][Full Text] [Related]
58. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.
Ueda Y; Hiyama E; Kamimatsuse A; Kamei N; Ogura K; Sueda T
J Pediatr Surg; 2011 Dec; 46(12):2221-7. PubMed ID: 22152854
[TBL] [Abstract][Full Text] [Related]
59. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
60. mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development.
Molina L; Yang H; Adebayo Michael AO; Oertel M; Bell A; Singh S; Chen X; Tao J; Monga SPS
Oncotarget; 2019 Feb; 10(15):1475-1490. PubMed ID: 30863496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
